Annual Review
Annual progress in tobacco medicine in 2023
Liu Zhao, Xiao Dan
Published 2024-02-12
Cite as Chin J Tuberc Respir Dis, 2024, 47(2): 163-166. DOI: 10.3760/cma.j.cn112147-20231030-00278
Abstract
Smoking is one of the major risk factors for several chronic non-infectious diseases, including chronic respiratory diseases, cancers, cardiovascular diseases, and diabetes, which has become a major public health issue in China. Tobacco control is proven to be the most effective and cost-effective strategy to reduce the risk of smoking-related disease and premature death. From October 2022 to September 2023, several high quality studies on tobacco medicine have been published. This review systematically summarizes the representative studies in terms of epidemiological study, clinical study, mechanism study, and tobacco control progress. These studies further highlight the concept that "tobacco smoking is the main evil for disease and tobacco control is the main good for disease prevention", which will promote the development of tobacco medicine in China.
Contributor Information
Liu Zhao
Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, World Health Organization Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention, Beijing 100029, China
Xiao Dan
Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, World Health Organization Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention, Beijing 100029, China
